PRIMARY IMMUNE THROMBOCYTOPENIA
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare immune diseases: managed access to VAY736 begins
Disease control AVAILABLEThis program provides access to the drug VAY736 (ianalumab) for patients with serious conditions like primary immune thrombocytopenia or Sjögren's syndrome who have no other treatment options. It is for patients who cannot join a clinical trial. The goal is to offer potential ben…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
Second dose of experimental drug offers hope for rare blood conditions
Disease control Recruiting nowThis study is for adults with two rare blood disorders—immune thrombocytopenia (ITP) and warm-antibody autoimmune hemolytic anemia (wAIHA)—who have already benefited from the drug ianalumab in a previous trial. Researchers want to see if a second course of ianalumab can control t…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New shot aims to boost platelets in chronic blood disorder
Disease control Recruiting nowThis study tests an experimental drug called PF-06835375 in adults with moderate to severe primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The drug is given as multiple injections under the skin. The main goal…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated May 05, 2026 11:54 UTC
-
500 kids with rare bleeding disorder to be tracked in major new study
Knowledge-focused Recruiting nowThis study follows 500 children aged 6–17 with immune thrombocytopenia (ITP), a rare disease where the immune system destroys platelets, causing bruising and bleeding. Researchers will collect data on symptoms, treatments, and recovery over time to build a model that predicts how…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated May 17, 2026 00:52 UTC